- Home
- PCRX
as of 03-11-2026 4:00pm EST
$22.83
+$0.39
+1.74%
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.0B | IPO Year: | 2010 |
| Target Price: | $35.33 | AVG Volume (30 days): | 736.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.16 | EPS Growth: | 107.44 |
| 52 Week Low/High: | $18.80 - $27.98 | Next Earning Date: | N/A |
| Revenue: | $541,533,000 | Revenue Growth: | 26.04% |
| Revenue Growth (this year): | 9.77% | Revenue Growth (next year): | 9.71% |
| P/E Ratio: | 140.38 | Index: | N/A |
| Free Cash Flow: | 136.7M | FCF Growth: | -23.55% |
Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)
WILLIAMS KRISTEN
Sell
Chief Administrative Officer
PCRX Feb 2, 2026
Avg Cost/Share
$20.53
Shares
13,137
Total Value
$269,702.61
Owned After
131,303
SEC Form 4
RIKER LAUREN
Sell
Senior Vice President, Finance
PCRX Feb 2, 2026
Avg Cost/Share
$20.81
Shares
4,000
Total Value
$83,240.00
Owned After
52,313.242
SEC Form 4
RIKER LAUREN
Sell
Senior Vice President, Finance
PCRX Jan 5, 2026
Avg Cost/Share
$24.24
Shares
1,416
Total Value
$34,323.84
Owned After
52,313.242
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| WILLIAMS KRISTEN | PCRX | Chief Administrative Officer | Feb 2, 2026 | Sell | $20.53 | 13,137 | $269,702.61 | 131,303 | |
| RIKER LAUREN | PCRX | Senior Vice President, Finance | Feb 2, 2026 | Sell | $20.81 | 4,000 | $83,240.00 | 52,313.242 | |
| RIKER LAUREN | PCRX | Senior Vice President, Finance | Jan 5, 2026 | Sell | $24.24 | 1,416 | $34,323.84 | 52,313.242 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
AI Prediction SELL
1D
-1.48%
$22.26
Act: -2.15%
5D
-6.55%
$21.11
Act: +1.26%
20D
-5.84%
$21.27
Price: $22.59 Prob +5D: 0% AUC: 1.000
0001628280-26-012238
pcrx-202602260001396814false00013968142026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2026
PACIRA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3506051-0619477 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 900 Brisbane, California 94005 (Address and Zip Code of Principal Executive Offices)
(650) 242-8052 (Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbolName of each exchange on which registered Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 26, 2026, Pacira BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit NumberDescription
99.1Press Release dated February 26, 2026
104Cover Page Interactive Data File (Formatted as Inline XBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Dated:February 26, 2026By:/s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 8, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 8, 2026 · 100% conf.
AI Prediction SELL
1D
-1.48%
$22.26
Act: -2.15%
5D
-6.55%
$21.11
Act: +1.26%
20D
-5.84%
$21.27
Price: $22.59 Prob +5D: 0% AUC: 1.000
0001628280-26-001335
pcrx-202601081/8/20260001396814false00013968142026-01-082026-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2026
PACIRA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3506051-0619477 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 900 Brisbane, California 94005 (Address and Zip Code of Principal Executive Offices)
(650) 242-8052 (Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbolName of each exchange on which registered Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 8, 2026, Pacira BioSciences, Inc. issued a press release announcing its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit NumberDescription
99.1Press Release dated January 8, 2026.
104Cover Page Interactive Data File (Formatted as Inline XBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Dated:January 8, 2026By:/s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001628280-25-050145
pcrx-202511060001396814false00013968142025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025
PACIRA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-35060 51-0619477
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
2000 Sierra Point Parkway, Suite 900 Brisbane, California 94005 (Address and Zip Code of Principal Executive Offices)
(650) 242-8052 (Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbolName of each exchange on which registered Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, Pacira BioSciences, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit NumberDescription
99.1Earnings Press Release dated November 6, 2025.
104Cover Page Interactive Data File (Formatted as Inline XBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Dated:November 6, 2025By:/s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary
Latest Pacira BioSciences Inc. News
PCRX Breaking Stock News: Dive into PCRX Ticker-Specific Updates for Smart Investing
Compare PCRX vs Leading Stocks
See how PCRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.